WEREWOLF THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-03-23
- WEREWOLF THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $13.66M.
- WEREWOLF THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 |
| 2021-12-31 | $13.66M 10-K · filed 2023-03-23 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |